Metabolic Syndrome and Cancer: From Bedside to Bench and Back

Extermann, Martine

doi:10.1159/000343621

Cited by 9 publications

(8 citation statements)

References 98 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, researchers held that the tumorigenesis in the body was a systemic disease [ 3 ]. Thus, more and more attention was paid to dysfunction and abnormality of metabolism caused by the etiology and pathogenesis of tumor [ 4 ]. And accumulating evidence suggested that altered lifestyle and obesity were closely linked to an increased risk of lung cancer [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study

Hao

Sang

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundNumerous studies reported that dyslipidemia was associated with cancer risk. However, few studies investigated the associations between dyslipidemia and non-small cell lung cancer (NSCLC).MethodsFour hundred twenty-four histologically confirmed NSCLC cases and 414 controls, matched for age and sex, were enrolled to examine the relationship between dyslipidemia and NSCLC. Demographic and clinical data were obtained from patients’ medical records and telephone interviews. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression.ResultsAbnormal triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) levels showed statistically significant coexistence with NSCLC compared with controls. Higher levels of TG were associated with a higher risk of NSCLC (OR = 1.541, 95% CI, (1.072–2.215)). The odds ratios (ORs) for NSCLC for normal and high levels of HDL-C versus those with a low level of HDL-C were 0.337(95% CI, (0.242–0.468)) and 0.288(95% CI, (0.185–0.448)), respectively. After adjustment for age, sex, smoking status, hypertension, body mass index, diabetes and lipid profiles, the adjusted OR for normal and high levels of HDL-C were 0.320(95% CI, (0.218–0.470)) and 0.233(95% CI, (0.134–0.407)), respectively. However, after adjustment, high levels of TG increased the risk of NSCLC but not significantly (OR = 1.052, 95% CI (0.671–1.649)).ConclusionsThis study provided evidence that dyslipidemia increased the risk of NSCLC in Chinese population.

show abstract

Section: Introductionmentioning

confidence: 99%

Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study

Hao

Sang

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Although the mechanisms are not fully understood, the importance of insulin resistance and hyperinsulinemia, as well as the role of insulin-like growth factor-1 (IGF-1) pathway, hyperglycemia, and production of toxic products such as advanced glycation dnd-products (AGEs) and reactive oxygen species (ROS) have emerged. These contribute to the occurrence of oxidative stress and cellular destruction, secretion of cytokines from adipocytes and other proteins with signalling properties, generally called adipokines, and chronic systemic inflammation, which accompanies obesity and leads to the production of inflammatory cytokines and the generation of tumorigenic environment [12][13][14][15][16].…”

Section: Mechanisms Linking Metabolic Syndrome To Cancermentioning

confidence: 99%

Metabolic syndrome and Cancer: Do they share common molecular pathways?

Veniou

Sofatzis

Kalantzis

et al. 2016

Forum of Clinical Oncology

View full text Add to dashboard Cite

Metabolic syndrome, a clustering of risk factors including obesity, has emerged as a global health plague. A lot of epidemiological and clinical evidence suggests that the metabolic syndrome is linked not only to cardiovascular diseases and diabetes mellitus type 2 but also to cancer development and progression. In this review the potential mechanisms tying the metabolic syndrome with cancer are presented. The role of insulin resistance and hyperinsulinemia, the activation of insulin-like growth factor-1 (IGF-1) pathway, and the induction of cytotoxic products are highlighted. Subsequent effects leading to oxidative stress, release of lipokines with signaling properties by adipocytes, development of a sustained systemic inflammation, production of inflammatory cytokines, and establishment of a tumorigenic environment are also discussed. The importance of the metabolic syndrome and obesity coupled with the deeper understanding of the underlying molecular mechanisms has trigger intensive clinical research with an aim to prevent the risk of cancer and improve outcomes. Moreover, the need for lifestyle changes with increased physical activity and improved dietary quality has been emerged as urgent health priority.

show abstract

“…Recently, many researchers considered tumorigenesis process in the body as a systemic disease [ 3 ]. So, research attentions focused on the etiology and cause of cancer that lead to dysfunction and abnormality of metabolism increasingly [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Case-control study of metabolic syndrome and ovarian cancer in Chinese population

et al. 2017

View full text Add to dashboard Cite

BackgroundRecent studies have proved metabolic syndrome (MetS) was linked to cancer risks. However, few data has examined the relationship between MetS and epithelial ovarian cancer (EOC).MethodsWe conducted a population-based case-control study in Tianjin Medical University Cancer Institute and Hospital, China (2010–2015) that enrolled 573 EOC patients and 1146 matched controls. Data were collected through in-person interviews, anthropometric measurement, and 8-h fasting bloods drawn. MetS was estimated by Chinese Diabetes Society (CDS) definition requiring presence of ≥3 of the following risk factors: 1) body mass index (BMI) ≥25.0 kg/m2,2) fasting plasma glucose ≥6.1 mmol/L or 2-h plasma glucose ≥ 7.8 mmol/L, 3) systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, 4) triglyceride (TG) ≥1.70 mmol/L or high-density lipoprotein cholesterol (HDL-C) < 1.0 mmol/L. Statistics were completed using chi-square tests and logistic regression analysis. The survival analysis was conducted by the Kaplan-Meier method and Cox proportional hazard regression models.ResultsMetS was significantly more prevalent among EOC (25.13%) than controls (6.89%). A statistically significant increase risk for EOC was observed for MetS (multivariable-adjusted OR = 3.187; 95% CI: 2.135–4.756). MetS was significantly associated with histological grade (P < 0.001), FIGO stage (P = 0.003), and lymph node (LN) status (P = 0.002) of EOC. In binary logistic regression analysis, the presence of MetS predicts the risk of advanced FIGO stage (OR = 2.155, 95% CI: 1.327–3.498, P = 0.002), lower differentiation (OR = 2.472, 95% CI: 1.164–5.250, P = 0.019), and LN metastasis (OR = 2.590, 95% CI: 1.089–6.160, P = 0.031) of EOC. Moreover, MetS is the independent factor for the evaluation of PFS and OS of EOC patients (both of them P < 0.001) in Cox proportional hazard model.ConclusionMetS is obviously related to increased EOC risk. EOC patients with MetS in Chinese population were found to have statistically significant tumor advanced stage, low differentiation, LN metastasis and poor prognosis.

show abstract

Metabolic Syndrome and Cancer: From Bedside to Bench and Back

Cited by 9 publications

References 98 publications

Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study

Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study

Metabolic syndrome and Cancer: Do they share common molecular pathways?

Case-control study of metabolic syndrome and ovarian cancer in Chinese population

Contact Info

Product

Resources

About